Literature DB >> 20856699

Office-based intraperitoneal chemotherapy for ovarian cancer.

William R Robinson1, Cathy Coberly, Julie Beyer, April Lewis, Carrie Ballard.   

Abstract

The challenges and opportunities when implementing an office-based intraperitoneal chemotherapy program.

Entities:  

Year:  2008        PMID： 20856699      PMCID： PMC2794017          DOI： 10.1200/JOP.0858503

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  13 in total

1.  Use of nitrogen mustard in treatment of serous effusions of neoplastic origin.

Authors:  A S WEISBERGER; B LEVINE; J P STORAASLI
Journal:  J Am Med Assoc       Date:  1955-12-31

2.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 3.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.

Authors:  Maurie Markman; Joan L Walker
Journal:  J Clin Oncol       Date:  2006-02-06       Impact factor: 44.544

4.  Catheter complications associated with intraperitoneal chemotherapy.

Authors:  C D Runowicz; P R Dottino; M K Shafir; M A Mark; C J Cohen
Journal:  Gynecol Oncol       Date:  1986-05       Impact factor: 5.482

5.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

6.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

7.  Intraperitoneal Therapy of Ovarian Cancer.

Authors: 
Journal:  Oncologist       Date:  1996

Review 8.  Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.

Authors:  R L Dedrick; M F Flessner
Journal:  J Natl Cancer Inst       Date:  1997-04-02       Impact factor: 13.506

9.  Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

Authors:  M Markman; E Rowinsky; T Hakes; B Reichman; W Jones; J L Lewis; S Rubin; J Curtin; R Barakat; M Phillips
Journal:  J Clin Oncol       Date:  1992-09       Impact factor: 44.544

10.  Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer.

Authors:  W R Robinson; N Davis; A S Rogers
Journal:  Int J Gynecol Cancer       Date:  2007-10-18       Impact factor: 3.437
View more
  3 in total

1.  Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Authors:  Paul Zarogoulidis; Ellada Eleftheriadou; Iordanis Sapardanis; Vasiliki Zarogoulidou; Helliel Lithoxopoulou; Theodoros Kontakiotis; Nikolaos Karamanos; George Zachariadis; Maria Mabroudi; Athanasios Zisimopoulos; Kostantinos Zarogoulidis
Journal:  Invest New Drugs       Date:  2011-07-08       Impact factor: 3.850

2.  Impact of shifting from office- to hospital-based treatment facilities on the administration of intraperitoneal chemotherapy for ovarian cancer.

Authors:  William R Robinson; Julie Beyer
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

Review 3.  Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

Authors:  Paul Zarogoulidis; Ekaterini Chatzaki; Konstantinos Porpodis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Eugene P Goldberg; Nikos Karamanos; Konstantinos Zarogoulidis
Journal:  Int J Nanomedicine       Date:  2012-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.